HDFC Pharma and Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹1,383 Cr

Expense Ratio

0.94%

ISIN

INF179KC1HO1

Minimum SIP

₹100

Exit Load

1.00%

Inception Date

04 Oct 2023

About this fund

HDFC Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by HDFC Mutual Fund. This fund has been in existence for 1 years, 1 months and 18 days, having been launched on 04-Oct-23.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹16.16, Assets Under Management (AUM) of 1382.60 Crores, and an expense ratio of 0.94%.

HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 53.20% since inception.
The fund's asset allocation comprises around 99.23% in equities, 0.00% in debts, and 0.77% in cash & cash equivalents.
You can start investing in HDFC Pharma and Healthcare Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+51.62%

+41.83% (Cat Avg.)

Since Inception

+53.20%

— (Cat Avg.)

Portfolio Summaryas of 31st October 2024

Equity	₹1,371.92 Cr	99.23%
Others	₹10.67 Cr	0.77%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹193.79 Cr	14.02%
Cipla Ltd	Equity	₹112.91 Cr	8.17%
Divi's Laboratories Ltd	Equity	₹109.31 Cr	7.91%
Lupin Ltd	Equity	₹86.44 Cr	6.25%
Ipca Laboratories Ltd	Equity	₹56.35 Cr	4.08%
Gland Pharma Ltd	Equity	₹55.35 Cr	4.00%
Aurobindo Pharma Ltd	Equity	₹47.58 Cr	3.44%
Piramal Pharma Ltd	Equity	₹47.11 Cr	3.41%
Dr Reddy's Laboratories Ltd	Equity	₹45.87 Cr	3.32%
Eris Lifesciences Ltd Registered Shs	Equity	₹45.28 Cr	3.27%
Krishna Institute of Medical Sciences Ltd	Equity	₹44.98 Cr	3.25%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹44.66 Cr	3.23%
Ajanta Pharma Ltd	Equity	₹43.11 Cr	3.12%
Vijaya Diagnostic Centre Ltd	Equity	₹42.11 Cr	3.05%
Glenmark Pharmaceuticals Ltd	Equity	₹40.39 Cr	2.92%
Wockhardt Ltd	Equity	₹34.88 Cr	2.52%
Zydus Lifesciences Ltd	Equity	₹34.81 Cr	2.52%
Fortis Healthcare Ltd	Equity	₹33.19 Cr	2.40%
Torrent Pharmaceuticals Ltd	Equity	₹31.24 Cr	2.26%
Metropolis Healthcare Ltd	Equity	₹30.4 Cr	2.20%
Jubilant Pharmova Ltd	Equity	₹27.39 Cr	1.98%
Ami Organics Ltd	Equity	₹26.52 Cr	1.92%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹24.91 Cr	1.80%
Pfizer Ltd	Equity	₹24.76 Cr	1.79%
Medi Assist Healthcare Services Ltd	Equity	₹22.98 Cr	1.66%
Treps - Tri-Party Repo	Cash - Repurchase Agreement	₹20.33 Cr	1.47%
Laurus Labs Ltd	Equity	₹17.46 Cr	1.26%
Bajaj Healthcare Limited - Prefential Issue	Equity	₹13.43 Cr	0.97%
Unichem Laboratories Ltd	Equity	₹12.79 Cr	0.92%
Thyrocare Technologies Ltd	Equity	₹12.53 Cr	0.91%
Net Current Assets	Cash	₹-9.65 Cr	0.70%
Medplus Health Services Ltd	Equity	₹9.12 Cr	0.66%
Alembic Pharmaceuticals Ltd	Equity	₹0.29 Cr	0.02%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹1,331.98 Cr	96.34%
Basic Materials	₹26.52 Cr	1.92%

Risk & Performance Ratios

Fund Managers

Dhruv Muchhal

Since October 2023

Nikhil Mathur

Since October 2023

Additional Scheme Detailsas of 31st October 2024

ISIN

INF179KC1HO1

Expense Ratio

0.94%

Exit Load

1.00%

Fund Size

₹1,383 Cr

Age

1 year 1 month

Lumpsum Minimum

₹100

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹28.64 Cr	43.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹881.52 Cr	37.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹881.52 Cr	35.4%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹40.84 Cr	37.9%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹208.21 Cr	45.8%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹208.21 Cr	43.1%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2770.21 Cr	38.2%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2770.21 Cr	36.2%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹852.28 Cr	36.6%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹19.81 Cr	37.0%

About the AMC

HDFC Mutual Fund

+91 22 66316333

https://www.hdfcfund.com/

Total AUM

₹7,39,434 Cr

Address

“HUL House”, 2nd Floor, Mumbai, 400 020

Other Funds by HDFC Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹1382.60 Cr	51.6%
HDFC Technology Fund Direct Growth Very High Risk	1.0%	1.0%	₹1316.72 Cr	38.1%
HDFC Fixed Maturity Plan 1162 Days March 2022 Series 46 Direct Growth Low Risk	-	0.0%	₹32.13 Cr	7.7%
HDFC FMP 1204D December 2022 (47) Direct Growth Low to Moderate Risk	-	-	-	7.9%
HDFC Fixed Maturity Plans 1269 Days March 2023 Series 47 Direct Growth Low to Moderate Risk	-	0.0%	-	8.3%
HDFC Fixed Maturity Plans 1359 Days September 2022 Series 46 Direct Growth Low to Moderate Risk	-	0.0%	-	8.2%
HDFC Fixed Maturity Plan 1406 Days August 2022 Series 46 Direct Growth Moderate Risk	-	0.0%	-	8.5%
HDFC Fixed Maturity Plans 1113 Days March 2019 Series 44 Plan 1 Direct Growth Moderate Risk	-	0.0%	-	-
HDFC Fixed Maturity Plan 1876 Days Series 46 Direct Growth Low to Moderate Risk	-	0.0%	₹31.46 Cr	8.8%
HDFC Fixed Maturity Plans Series 46 1158D July 2022 Direct Growth Low to Moderate Risk	-	0.0%	-	7.9%
HDFC Fixed Maturity Plan 1861 Days Series 46 Direct Growth Low to Moderate Risk	-	0.0%	₹449.71 Cr	8.9%
HDFC FMP 2638D February 2023 (47) Direct Growth Moderate Risk	-	0.0%	-	10.1%
HDFC Fixed Maturity Plans 1127 Days April 2019 Series 44 Plan 1 Direct Growth Moderate Risk	-	-	-	-
HDFC Balanced Advantage Fund Direct Growth Very High Risk	0.7%	1.0%	₹94865.65 Cr	24.7%
HDFC Hybrid Equity Fund Direct Growth Very High Risk	1.0%	1.0%	₹24068.32 Cr	18.5%
HDFC Dynamic PE Ratio Fund of Funds Plan A Direct Growth High Risk	0.2%	1.0%	₹48.49 Cr	16.6%
HDFC Small Cap Fund Direct Growth Very High Risk	0.7%	1.0%	₹33504.02 Cr	23.2%
HDFC Housing Opportunities Fund Direct Growth Very High Risk	1.2%	1.0%	₹1453.04 Cr	24.6%
HDFC Large and Mid Cap Fund Direct Growth Very High Risk	0.9%	1.0%	₹23484.62 Cr	28.2%
HDFC Nifty G-Sec July 2031 Index Fund Direct Growth Moderate Risk	0.2%	0.0%	₹660.11 Cr	9.8%
HDFC Nifty G-sec Dec 2026 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹1306.25 Cr	8.1%
HDFC Business Cycle Fund Direct Growth Very High Risk	0.8%	1.0%	₹2978.22 Cr	21.8%
HDFC NIFTY Smallcap 250 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹348.22 Cr	28.5%
HDFC Credit Risk Debt Fund Direct Growth Moderately High risk	1.0%	1.0%	₹7427.02 Cr	9.0%
HDFC Nifty SDL Oct 2026 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹191.12 Cr	8.5%
HDFC Banking and PSU Debt Fund Direct Growth Moderate Risk	0.4%	0.0%	₹5885.66 Cr	8.4%
HDFC Banking & Financial Services Fund Direct Growth Very High Risk	0.7%	1.0%	₹3650.38 Cr	17.7%
HDFC Non-Cyclical Consumer Fund Direct Growth Very High Risk	1.1%	1.0%	₹884.45 Cr	26.1%
HDFC Asset Allocator Fund of Funds Direct Growth High Risk	0.1%	1.0%	₹3308.49 Cr	20.7%
HDFC Gold Fund Direct Growth High Risk	0.2%	1.0%	₹2795.03 Cr	24.3%
HDFC Gilt Fund Direct Growth Moderate Risk	0.5%	0.0%	₹2815.51 Cr	9.5%
HDFC Dynamic Debt Fund Direct Growth Moderate Risk	0.8%	0.0%	₹786.47 Cr	9.7%
HDFC Medium Term Debt Fund Direct Growth Moderately High risk	0.7%	0.0%	₹3984.88 Cr	8.9%
HDFC Income Fund Direct Growth Moderate Risk	0.8%	0.0%	₹858.98 Cr	9.7%
HDFC Infrastructure Fund Direct Growth Very High Risk	1.1%	1.0%	₹2515.87 Cr	33.9%
HDFC Liquid Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹67330.71 Cr	7.4%
HDFC Corporate Bond Fund Direct Growth Moderate Risk	0.4%	0.0%	₹32510.60 Cr	8.9%
HDFC Mid-Cap Opportunities Fund Direct Growth Very High Risk	0.7%	1.0%	₹75037.43 Cr	33.1%
HDFC Hybrid Debt Fund Direct Growth Moderately High risk	1.2%	1.0%	₹3299.16 Cr	13.8%
HDFC TaxSaver Direct Growth Very High Risk	1.1%	0.0%	₹15934.95 Cr	33.8%
HDFC Multi - Asset Fund Direct Growth High Risk	0.7%	1.0%	₹3759.76 Cr	20.2%
HDFC Equity Savings Fund Direct Growth Moderately High risk	0.9%	1.0%	₹5463.01 Cr	14.9%
HDFC Short Term Debt Fund Direct Growth Moderate Risk	0.4%	0.0%	₹14972.01 Cr	8.7%
HDFC Top 100 Fund Direct Growth Very High Risk	1.0%	1.0%	₹36467.34 Cr	22.8%
HDFC S&P BSE 500 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹184.01 Cr	23.6%
HDFC Nifty Midcap 150 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹246.47 Cr	29.4%
HDFC Dividend Yield Fund Direct Growth Very High Risk	0.7%	1.0%	₹6124.17 Cr	27.1%
HDFC Low Duration Fund Direct Growth Low to Moderate Risk	0.5%	0.0%	₹17570.32 Cr	8.1%
HDFC Arbitrage Fund Direct Growth Low Risk	0.4%	0.0%	₹16605.90 Cr	8.4%
HDFC Capital Builder Value Fund Direct Growth Very High Risk	1.0%	1.0%	₹7429.39 Cr	32.1%

Risk Level

Your principal amount will be at Very High Risk

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

What is the current NAV of HDFC Pharma and Healthcare Fund Direct Growth?

The NAV of HDFC Pharma and Healthcare Fund Direct Growth, as of 21-Nov-2024, is ₹16.16.

What is the portfolio composition of HDFC Pharma and Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 99.23% in equities, 0.00% in bonds, and 0.77% in cash and cash equivalents.

Who manages the HDFC Pharma and Healthcare Fund Direct Growth?

The fund managers responsible for HDFC Pharma and Healthcare Fund Direct Growth are:-

Dhruv Muchhal
Nikhil Mathur

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Our weekly expert newsletter on stories that matter to your money.

Knowledge Repository

Bonds

IPA

Mutual Funds

Portfolio Management Services

About

Investment Philosophy

Legal

Returns & Cancellation

Security

Terms & Disclosure

KYC Check

©2021-2024 Dezerv. All Rights Reserved

Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

HDFC Pharma and Healthcare Fund Direct Growth

Fund Overview